Pro re nata medication for psychoses: an audit of practice in two metropolitan hospitals

References

• Jablensky A, McGrath J, Hermann H, et al. People living with psychotic illness: an Australian study 1997–98. National Survey of Mental Health and Wellbeing. Commonwealth Department of Health and Aged Care, Canberra 1999, Report 4.
   Google Scholar
• Mason A, De Wolfe A. Use of drugs in a mental hospital: as needed (PRN) antipsychotic medications. Current Therapeutic Research 1974; 16: 853–860
   Web of Science ®Google Scholar
• Fishel A, Ferreiro B, Rynerson M, Nickel M, Jackson B, Hannah B. As needed psychotropic medications: prevalence indications and results. Journal of Psychosocial Nursing 1994; 32: 27–32
   PubMedGoogle Scholar
• McLaren S, Browne F, Taylor P. A study of psychotropic medication given ‘as required’ in a secure regional unit. British Journal of Psychiatry 1990; 156: 732–735
   PubMed Web of Science ®Google Scholar
• Walker R. PRN psychotropic drug use on a psychiatric unit. Psychiatric Quarterly 1991; 62: 1–8
   PubMedGoogle Scholar
• Craig J, Thomas J, Bracken J. An epidemiological study of prn/stat medication use in a state psychiatric hospital. Annals of Clinical Psychiatry 1995; 7: 57–64
   PubMedGoogle Scholar
• Craven J, Voore P, Voineskos G. PRN medication in psychiatric inpatients. Canadian Journal of Psychiatry 1987; 32: 199–203
   PubMed Web of Science ®Google Scholar
• Parker G, Lambert T, McGrath J, McGorry P, Tiller J. Neuroleptic management of schizophrenia: a survey and commentary on Australian psychiatric practice. Australia and New Zealand Journal of Psychiatry 1998; 32: 50–58
   PubMed Web of Science ®Google Scholar
• Miller C, Mohr F, Umbricht D. The prevalence of acute extrapyramidal symptoms in patients treated with clozapine, risperidone and conventional antipsychotics. Journal of Clinical Psychiatry 1998; 59: 69–75
   PubMed Web of Science ®Google Scholar
• Collaborative Working Group on Clinical Trial Evaluations. Assesssment of EPS and tardive dyskinesia in clinical trials. Journal of Clinical Psychiatry 1998; 59(Suppl. 12)23–27
   Google Scholar
• Collaborative Working Group on Clinical Trial Evaluations. Assessing the effects of atypical antipsychotics on negative symptoms. Journal of Clinical Psychiatry 1998; 59(Suppl. 12)28–34
   Google Scholar
• Van Putten T. Why do schizophrenic patients refuse to take their drugs?. Archives of General Psychiatry 1974; 31: 67–72
   PubMed Web of Science ®Google Scholar
• Fleischacker W, Meise U, Gunter V. Compliance with antipsychotic drug treatment: Influence of side effects. Acta Psychiatrica Scandinavica 1994; 382(Suppl.)11–15
   Google Scholar
• Marder S. Antipsychotic drugs and relapse prevention. Schizophrenia Research 1999; 35: S87–S92
   PubMed Web of Science ®Google Scholar
• Desai N, Huq Z, Martin S, McDonald G. Switching from depot antipsychotics to risperidone: results of a study of chronic schizophrenia. Advances in Therapy 1999; 16: 78–87
   PubMed Web of Science ®Google Scholar
• Dubin W, Weiss K, Dorn J. Pharmacotherapy of psychiatric emergencies. Journal of Clinical Psychopharmacology 1986; 6: 210–222
   PubMed Web of Science ®Google Scholar
• Dubin W. Rapid tranquillisation: antipsychotics or benzodiazepines. Journal of Clinical Psychiatry 1988; 49(Suppl.)5–10
   PubMed Web of Science ®Google Scholar
• Garza-Trevino E, Hollister L, Overall J, Alexander W. Efficacy of combinations of intramuscular antipsychotics and sedativehypnotics for control of psychotic agitation. American Journal of Psychiatry 1989; 146: 1599–1601
   Web of Science ®Google Scholar
• Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double blind emergency department study. American Journal of Emergency Medicine 1997; 15: 335–340
   PubMed Web of Science ®Google Scholar
• Salzman C, Solomon D, Miyawaki E, Glassman R, Rood L, Flowers E. Parenteral lorazepam vs parenteral haloperidol for the control of psychotic disruptive behaviour. Journal of Clinical Psychiatry 1991; 52: 177–180
   PubMed Web of Science ®Google Scholar
• Foster S, Kessel J, Berman M, Simpson G. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. International Clinical Psychopharmacology 1997; 12: 175–179
   PubMed Web of Science ®Google Scholar
• Demczar D, Levin G. Use of atypical antipsychotics on an as-needed basis. Journal of Pharmacy Technology 1996; 12: 145–148
   Google Scholar
• RANZCP Committee on Psychotropic Drugs and Other Physical Treatments. Response to ‘Cardiotoxicity associated with the use of intravenous haloperidol’ (letter). Australian and New Zealand Journal of Psychiatry 1999; 33: 943–944
   PubMed Web of Science ®Google Scholar
• Gray R, Smedley N, Thomas B. Focus on Mental Health Nursing. Administration of PRN medication by mental health nurses. British Journal of Nursing 1996; 5: 1317–1322
   PubMedGoogle Scholar
• McKenzie A, Kudinoff T, Benson A, Archillingham A. Administration of PRN medication: a descriptive study of nursing practice. Australia and New Zealand Journal of Mental Health Nursing 1999; 8: 187–191
   PubMedGoogle Scholar
• Bazire S. Drug treatment options in psychiatric illness. Psychotropic Drug Directory 1999, S Bazire. Mark Allen Publishing, Salisbury 1999; 1–115
   Google Scholar
• Mould D, DeFeo T, Reele S, Millac G, Patel H. Simultaneous modeling of the pharmacokinetics and pharmacodynamics of midazolam and diazepam. Clinical Pharmacology and Therapeutics 1995; 58: 35–43
   PubMed Web of Science ®Google Scholar
• Lambert T. Utility for neuroleptic dose conversion. Multimedia in Psychiatry Unit. University of Melbourne, Melbourne 1998, (CD-ROM).
   Google Scholar
• Siegfried N. A review of comorbidity: major mental illness and problematic substance abuse. Australian and New Zealand Journal of Psychiatry 1998; 32: 707–717
   PubMed Web of Science ®Google Scholar
• Whitworth A, Fleischacker W. Adverse effects of antipsychotic drugs. International Clinical Psychopharmacology 1995; 9(Suppl. 5)21–27
   PubMed Web of Science ®Google Scholar
• Milling R, Faulkner L, Craig J. Problems in the recognition and treatment of patients with dual diagnosis. Journal of Substance Abuse Treatment 1994; 11: 267–271
   PubMed Web of Science ®Google Scholar
• Geffen J, Cameron A, Sorensen L, Stokes J, Roberts M S, Geffen L. PRN medication for psychoses: the knowledge and beliefs of mental health doctors and nurses. Australian and New Zealand Journal of Psychiatry 2002; 36: 642–648
   PubMed Web of Science ®Google Scholar
• Kane J, McGlashan T. Treatment of schizophrenia. Lancet 1995; 346: 820–825
   PubMed Web of Science ®Google Scholar
• Wolkowitz O, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. American Journal of Psychiatry 1991; 148: 714–726
   PubMed Web of Science ®Google Scholar